<DOC>
	<DOCNO>NCT00302458</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , five-period crossover study examine likability repeat administration immediate release methylphenidate hydrochloride ( IR-MPH 40 mg ) OROS速-MPH ( CONCERTA速 72 mg ) healthy adult . Hypotheses follow : - Hypothesis 1 : subjective feeling detection likeability great period IR-MPH administration OROS-MPH administration irregardless sequence ; - Hypothesis 2 : great rating feeling detection likeability associate period rapid change plasma d-MPH magnitude plasma d-MPH concentration ( OROS-MPH IR-MPH condition coincide ) , - Hypothesis 3 : subjective feeling dislike great two condition IR-MPH second condition .</brief_summary>
	<brief_title>A Study Repeat Dosing OROS速 Methylphenidate Hydrochloride ( CONCERTA速 ) Immediate Release Methylphenidate Hydrochloride Healthy Adults</brief_title>
	<detailed_description>The main goal study ass whether abuse liability potential delayed , repeated administration different formulation MPH moderate oral delivery system delivery system slow onset may safer one rapid early release . To end , investigator compare repeat administration orally administer , therapeutic dos short ( IR-MPH ) long-acting formulation MPH ( OROS-MPH ) follow area : 1. pharmacokinetic profile MPH assess rate onset MPH action ( indexed change plasma level ) 2. abuse liability ( indexed detection likeability ) . The investigator test combination initial administration delay ( repeat ) administration two formulation : IR-MPH IR-MPH ; IR-MPH OROS-MPH ; OROS-MPH IR-MPH ; OROS-MPH OROS-MPH , placebo placebo .</detailed_description>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Males nonpregnant , nonlactating female . With exception woman postmenopausal minimum 12 month prior screen undergone hysterectomy bilateral oophorectomy , female subject must negative urine pregnancy test screen admission research unit . All male female subject must use medically acceptable form birth control least one month prior screen willing continue use study . Medically acceptable form birth control include abstinence , hormonal contraceptive , diaphragm spermicide , condom spermicide , intrauterine device , surgical sterilization ( include vasectomy male partner [ ] ) . 2 . Eighteen ( 18 ) 45 year age , inclusive 3 . Based medical history , limited physical examination ( neurologic cardiac ) and/or lab result , consider healthy free condition may interfere participation study . Any abnormality screen result electrocardiogram ( ECG ) laboratory test must determine clinically significant investigator . 4 . Agree use prescription stimulant ( except study medication ) study 5 . Have venous access sufficient blood sampling determine clinical examination 6 . Weigh least 100 pound screen 7 . Agree available return study center five fullday ( approximately 18 hour ) study visit hold five 30 day apart within 22week period , willing complete protocolspecified assessment . 8 . Able read comprehend English 1 . Marked anxiety , tension , agitation since drug may aggravate symptom 2 . Known hypersensitivity methylphenidate component Concerta Ritalin 3 . Subjects glaucoma 4 . Motor tics family history diagnosis Tourette 's syndrome 5 . Treated monoamine oxidase inhibitor ( MAOIs ) within 14 day discontinuation treatment MAOIs 6 . Presence history medically diagnose , clinically significant Axis I psychiatric disorder ( include substance use disorder , bipolar disorder , psychotic disorder ) 7 . Scores Baseline Scales : Hamilton Depression Scale &gt; 17 ( possible 67 21item scale ) ( Hamilton 1960 ) Beck Depression Inventory &gt; 19 ( possible 63 21item scale ) ( Beck et al 1961 ) Hamilton Anxiety Scale &gt; 21 ( possible 56 14item scale ) ( Hamilton 1959 ) 8 . Any clinically significant chronic disease unstable medical abnormality history physical examination , include hypertension , hyperthyroidism , seizure disorder , history myocardial infarction stroke , history cardiac arrhythmia heart murmur ( uncomplicated mitral valve prolapse ) 9 . Clinically significant abnormal baseline laboratory value include follow : Values &gt; 20 % upper range laboratory standard basic metabolic screen complete blood count Exclusionary blood pressure &gt; 140 ( systolic ) 90 ( diastolic ) . Exclusionary ECG parameter : QTC &gt; 460 msec , QRS &gt; 120 msec , PR &gt; 200 msec . Subjects ECG evidence ischemia arrhythmia review independent cardiologist 10 . Currently take require follow medication : Clonidine alpha2 adrenergic receptor agonists Tricyclic antidepressant Selective serotonin reuptake inhibitor ( SSRIs ) Theophylline Coumarin anticoagulants Anticonvulsants Prescription stimulant 11 . Have take SSRI 35 day initiation study medication 12 . Currently physically dependent benzodiazepine , opiates alcohol determine clinical evaluation positive urine drug screen screen 13 . Preexisting severe gastrointestinal narrowing ( pathologic iatrogenic , example : small bowel inflammatory disease , `` short gut '' syndrome due adhesion decrease transit time , past history peritonitis , cystic fibrosis , chronic intestinal pseudoabsorption , Meckel 's diverticulum ) 14 . Unable swallow study medication whole 15 . Have significant blood loss ( &gt; 500 mL ) donate blood 30 day precede dose 16 . Have positive urine drug screen screen 17 . Have take investigational medication product within past 30 day 18 . Have take prescription medication ( exception birth control method ) within seven day screen anticipated need medication , overthecounter product ( acetaminophen ) , herbal supplement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>healthy volunteer</keyword>
</DOC>